Bioavailability and Food Effect Study of TKI258 (CSF Capsules vs. FMI Capsules)in Adult Patients With Advanced Solid Tumors
This study will evaluate the relative bioavailability of 2 oral formulations of TKI258, and the effect of food on the bioavailability of TKI258, in adult patients with advanced solid tumor
Neoplasms|Cancer|Tumors
DRUG: TKI258 (dovitinib)
Determine the relative bioavailability of the final market image form of TKI258 (monohydrate capsules) as compared to the clinical service form of TKI258 (anhydrate capsules), 9 days|Determine the effect of food on the bioavailability of TKI258, 22 days
Characterize the safety and tolerability of TKI258, including acute and chronic toxicities, Up to 28 days after the last dose of study drug|Evaluate preliminary evidence of anti-tumor activity of TKI258 in patients with advanced solid tumors., Every 8 weeks until progression of disease
This study will evaluate the relative bioavailability of 2 oral formulations of TKI258, and the effect of food on the bioavailability of TKI258, in adult patients with advanced solid tumor